197 related articles for article (PubMed ID: 36177059)
1. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
[TBL] [Abstract][Full Text] [Related]
2. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
[TBL] [Abstract][Full Text] [Related]
4. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
5. The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells.
Momen Razmgah M; Ghahremanloo A; Javid H; AlAlikhan A; Afshari AR; Hashemy SI
Mol Biol Rep; 2022 Oct; 49(10):9307-9314. PubMed ID: 35960409
[TBL] [Abstract][Full Text] [Related]
6. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
7. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
[TBL] [Abstract][Full Text] [Related]
8. Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients.
Robinson P; Rosso M; Muñoz M
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983138
[TBL] [Abstract][Full Text] [Related]
9. The substance P/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells.
Golestaneh M; Firoozrai M; Javid H; Hashemy SI
Mol Biol Rep; 2022 Jun; 49(6):4893-4900. PubMed ID: 35429316
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-
Ghahremanloo A; Javid H; Afshari AR; Hashemy SI
Biomed Res Int; 2021; 2021():1383878. PubMed ID: 34395609
[TBL] [Abstract][Full Text] [Related]
11. The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages.
Zhao XN; Bai ZZ; Li CH; Sheng CL; Li HY
Drug Des Devel Ther; 2020; 14():1943-1952. PubMed ID: 32546961
[TBL] [Abstract][Full Text] [Related]
12. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.
Chen KT; Hour MJ; Tsai SC; Chung JG; Kuo SC; Lu CC; Chiu YJ; Chuang YH; Yang JS
Int J Oncol; 2011 Sep; 39(3):611-9. PubMed ID: 21667022
[TBL] [Abstract][Full Text] [Related]
13. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
14. Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cells.
Chen HJ; Lin CM; Lee CY; Shih NC; Peng SF; Tsuzuki M; Amagaya S; Huang WW; Yang JS
Oncol Rep; 2013 Aug; 30(2):925-32. PubMed ID: 23708932
[TBL] [Abstract][Full Text] [Related]
15. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.
Kolorz J; Demir S; Gottschlich A; Beirith I; Ilmer M; Lüthy D; Walz C; Dorostkar MM; Magg T; Hauck F; von Schweinitz D; Kobold S; Kappler R; Berger M
Curr Oncol; 2021 Dec; 29(1):94-110. PubMed ID: 35049682
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation.
Cao X; Yang Y; Zhou W; Wang Y; Wang X; Ge X; Wang F; Zhou F; Deng X; Miao L
BMC Cancer; 2023 May; 23(1):471. PubMed ID: 37221457
[TBL] [Abstract][Full Text] [Related]
17. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
[TBL] [Abstract][Full Text] [Related]
19. The in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-aminolevulinic acid in glioblastoma.
Ebrahimi S; Mirzavi F; Hashemy SI; Khaleghi Ghadiri M; Stummer W; Gorji A
Biofactors; 2023; 49(4):900-911. PubMed ID: 37092793
[TBL] [Abstract][Full Text] [Related]
20. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis.
Martinez AN; Burmeister AR; Ramesh G; Doyle-Meyers L; Marriott I; Philipp MT
J Neuroinflammation; 2017 Feb; 14(1):37. PubMed ID: 28202084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
